While earlier approaches focused on enhancing innate immune engagement, Hiltbrunner et al. implemented a molecular engineering approach to broaden antigenic repertoire and enhance T cell engagement by incorporating full‐length tumor antigens into DEXs.[206] This supported concurrent activation of MHC class I and II, effectively bridging CD8+ and CD4+ T cell responses. The gene discussed is CD8A; the disease is neoplasm.